Video Experimental Relacionado
Updated: Aug 7, 2026
08:33
An Ex vivo Culture System to Study Thyroid Development
Published on: June 6, 2014
Los complejos inmunológicos circulantes y las inmunoglobulinas estimulantes de la tiroides antes, durante y después
Lancet (London, England)
|June 28, 1980
Resumen
Los complejos inmunes circulantes (CIC) pueden enmascarar las inmunoglobulinas estimulantes de la tiroides (TSI) en la enfermedad de Graves. El desarrollo de CIC durante el tratamiento se correlacionó con la desaparición de TSI, lo que sugiere un retorno a la tolerancia inmune.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Inmunología Inmunología.
- Enfermedades autoinmunes Las enfermedades autoinmunes.
Sus antecedentes:
- La enfermedad de Graves es un trastorno autoinmune caracterizado por la producción de inmunoglobulinas estimulantes de la tiroides (TSI).
- El papel de los complejos inmunes circulantes (CIC) en la patogénesis y el monitoreo de la enfermedad de Graves sigue siendo incompletamente entendido.
Objetivo del estudio:
- Investigar la relación entre los niveles de TSI y CIC en pacientes con enfermedad de Graves.
- Evaluar el impacto del tratamiento con fármacos antitiroideos en la ETI y el CIC.
- Explorar el papel potencial de CIC en el desarrollo de la tolerancia inmune en la enfermedad de Graves.
Principales métodos:
- Los sueros de 57 pacientes con enfermedad de Graves no tratados fueron analizados para TSI y CIC.
- Se recogieron muestras antes, durante y después del tratamiento con fármacos antitiroideos.
- El índice de la ETI y la presencia de CIC se cuantificaron utilizando ensayos de laboratorio establecidos.
Principales resultados:
- En los pacientes no tratados, el 72% tenía TSI positivo y el 30% tenía CIC. CIC fueron más frecuentes en pacientes con ETI negativo.
- Durante el tratamiento inicial, el 85% de los pacientes desarrollaron CIC, coincidiendo con la desaparición de TSI.
- TSI no reapareció incluso después de que los CIC ya no fueran detectables más adelante en el tratamiento.
Conclusiones:
- Los complejos inmunes circulantes pueden interferir con la detección de TSI en la enfermedad de Graves.
- El desarrollo de CIC durante el tratamiento puede significar el restablecimiento de la tolerancia inmune a los receptores de TSH.
- Esto sugiere un mecanismo potencial para la remisión en la enfermedad de Graves.
Videos de Conceptos Relacionados
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:19Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...